全文获取类型
收费全文 | 1991篇 |
免费 | 138篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 52篇 |
妇产科学 | 55篇 |
基础医学 | 263篇 |
口腔科学 | 27篇 |
临床医学 | 200篇 |
内科学 | 380篇 |
皮肤病学 | 34篇 |
神经病学 | 61篇 |
特种医学 | 203篇 |
外科学 | 269篇 |
综合类 | 52篇 |
预防医学 | 86篇 |
眼科学 | 8篇 |
药学 | 190篇 |
肿瘤学 | 256篇 |
出版年
2021年 | 17篇 |
2020年 | 12篇 |
2019年 | 12篇 |
2018年 | 19篇 |
2017年 | 24篇 |
2016年 | 29篇 |
2015年 | 23篇 |
2014年 | 40篇 |
2013年 | 55篇 |
2012年 | 73篇 |
2011年 | 77篇 |
2010年 | 41篇 |
2009年 | 57篇 |
2008年 | 69篇 |
2007年 | 83篇 |
2006年 | 74篇 |
2005年 | 84篇 |
2004年 | 63篇 |
2003年 | 63篇 |
2002年 | 66篇 |
2001年 | 70篇 |
2000年 | 64篇 |
1999年 | 72篇 |
1998年 | 64篇 |
1997年 | 61篇 |
1996年 | 53篇 |
1995年 | 50篇 |
1994年 | 28篇 |
1993年 | 33篇 |
1992年 | 46篇 |
1991年 | 46篇 |
1990年 | 40篇 |
1989年 | 49篇 |
1988年 | 46篇 |
1987年 | 53篇 |
1986年 | 46篇 |
1985年 | 46篇 |
1984年 | 27篇 |
1983年 | 24篇 |
1982年 | 31篇 |
1981年 | 23篇 |
1980年 | 33篇 |
1979年 | 24篇 |
1978年 | 25篇 |
1977年 | 31篇 |
1976年 | 19篇 |
1975年 | 10篇 |
1974年 | 10篇 |
1973年 | 10篇 |
1969年 | 7篇 |
排序方式: 共有2143条查询结果,搜索用时 687 毫秒
101.
102.
103.
104.
105.
Shen H Liu Z Strom SS Spitz MR Lee JE Gershenwald JE Ross MI Mansfield PF Duvic M Ananthaswamy HN Wei Q 《The Journal of investigative dermatology》2003,121(6):1510-1514
The p53 gene plays an important role in cell cycle control, facilitating DNA repair activities in response to DNA damage. Aberrant cell cycle control impairs DNA repair and increases the probability of mutations that can lead to carcinogenesis. The p53 gene is polymorphic at codon 72 (Arg/Pro) of its protein, which is functionally distinct, leading to inquiry into its role in carcinogenesis. In this hospital-based case-control study of 289 newly diagnosed patients with melanoma and 308 cancer-free control subjects, we evaluated whether the p53 codon 72 variant is associated with risk of cutaneous melanoma (CM). The controls were frequency-matched to the cases by age, sex, and ethnicity. The frequency of the p53 Arg allele was 78.2% in cases and 73.2% in controls (p=0.045), and the genotype frequencies of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 62.6%, 31.1%, and 6.3%, respectively, in the cases, and 53.9%, 38.6%, and 7.5%, respectively, in the controls (p=0.096). Logistic regression analysis revealed that the p53 Arg/Arg genotype was associated with a significantly increased risk of melanoma (adjusted odds ratio (OR)=1.43; 95% confidence interval (CI)=1.02-2.02) compared with other genotypes, and this association was more evident in subgroups of older subjects (OR=2.32; 95% CI=1.39-388), and subjects with Fitzpatrick's skin type III or IV (OR=1.69; 95% CI=1.11-2.59). In conclusion, this study found some evidence that in subjects over 50, p53 Arg/Arg genotype is associated with increased risk of CM as compared to genotypes Arg/Pro or Pro/Pro. Further larger studies are needed to substantiate our findings. 相似文献
106.
The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression 总被引:4,自引:0,他引:4
BACKGROUND: In many situations, anti-CD154 (CD40 ligand) monoclonal antibody (mAb) treatment is very potent in producing allograft tolerance. In accordance to our previously reported results, combined donor specific transfusion (DST)3 plus anti-CD154 mAb (MR1) treatment enables the permanent engraftment of DBA/2 (H-2(d)) islets into B6AF1 (H-2(b/kd)) recipients in all cases. It has been widely assumed that the MR1 anti-154 is a noncytolytic neutralizing mAb, and it exerts immune suppressive effects by blockade of CD40/CD154 signal pathway. In this study, we sought to test the role of complement dependent cytotoxicity (CDC) immune effector mechanism in MR1 anti-CD154 induced immunosuppression. METHODS: We have evaluated the contributions of CDC in the context of the potent tolerizing effects of DST plus anti-CD154 mAb treatment regiment in recipients of islet allografts. We have used CD40 knockout (KO) mice and complement C5 deficient mice DBA/2 as islet allograft recipients as well as cobra venom factor (CVF), a complement blocker, treatment. RESULTS: The absence of direct and indirect CD40/CD154 pathway signals does not prevent islet allograft acute rejection. Interestingly, MR1 anti-CD154 induces islet allograft tolerance in the absence of CD40/CD154 pathway. In a wild-type major histocompatibility complex (MHC) mismatched strain combination, DST results in accelerated islet allograft rejection. Combination of DST and MR1 anti-CD154 treatment prevents presensitization and permits permanent engraftment. However, administration of CVF abolishes the tolerance induction. Moreover, DST plus MR1 anti-CD154 regiment, a potent tolerizing therapy, does not prevent acute islet allograft rejection when complement C5 deficient DBA/2 mice are used as recipients. Thus, the mechanisms of the tolerizing effects by MR1 anti-CD154 are not limited to blockade of CD40/CD154 signals. The CDC immune effector mechanism contributes to MR1 anti-CD154 induced immunosuppression. 相似文献
107.
Zhu Y Spitz MR Strom S Tomlinson GE Amos CI Minna JD Wu X 《International journal of cancer. Journal international du cancer》2002,102(5):536-540
Cytogenetic aberrations on chromosome 9 have been reported to be one of the most frequent genetic changes in lung tumorigenesis. Although many of these changes have been detected in lung carcinoma specimens, there is growing evidence showing the concordance between chromosomal alterations in primary lung tumors and peripheral blood lymphocytes (PBLs). We investigated whether spontaneous aberrations on chromosome 9 in PBLs are associated with the presence of lung cancer and with a family history of cancer. A personal interview, to construct a detailed epidemiologic profile including family history of cancer, was conducted on 174 lung cancer cases and 162 matched controls. One hundred metaphases from PBLs of each subject were analyzed for chromosome 9 aberrations using the whole chromosome painting technique. Overall, the mean proportion of individuals with chromosome 9 abnormalities in their PBLs was significantly higher in cases (96.0%) than in controls (60.5%) (p < 0.05). After adjustment by age, gender, ethnicity, family size, and pack-years, there was a 16.63-fold significantly elevated odds ratio (OR) for lung cancer associated with chromosome 9 aberrations. When subjects were categorized by frequencies of the chromosome 9 lesions, we observed significantly increased odds ratios of 11.13 (4.66, 26.58) and 27.45 (11.15, 67.54) for individuals with 1 chromosome 9 aberration and >/=2 chromosome 9 aberrations, respectively. By performing family history analyses, we further observed that control individuals with chromosome 9 aberrations were more likely to report a family history of any cancer (OR = 1.67 [0.84, 3.32]) and lung cancer (OR = 2.49 [0.81, 7.67]). Our findings suggest that chromosome 9 aberrations in PBLs might be considered a marker of lung cancer predisposition and may be associated with familial aggregation of cancer. 相似文献
108.
Breast IMRT: new tools leading to new vision 总被引:2,自引:0,他引:2
Strom EA 《International journal of radiation oncology, biology, physics》2002,54(5):116-1298
109.
Huang E Buchholz TA Meric F Krishnamurthy S Mirza NQ Ames FC Feig BW Kuerer HM Ross MI Singletary SE McNeese MD Strom EA Hunt KK 《Cancer》2002,95(10):2059-2067
BACKGROUND: To distinguish true local recurrences (TR) from new primary tumors (NP) and to assess whether this distinction has prognostic value in patients who develop ipsilateral breast tumor recurrences (IBTR) after breast-conserving surgery and radiotherapy. METHODS: Between 1970 and 1994, 1339 patients underwent breast-conserving surgery at The University of Texas M. D. Anderson Cancer Center for ductal carcinoma in situ or invasive carcinoma. Of these patients, 139 (10.4%) had an IBTR as the first site of failure. For the 126 patients with clinical data available for retrospective review, we classified the IBTR as a TR if it was located within 3 cm of the primary tumor bed and was of the same histologic subtype. All other IBTRs were designated NP. RESULTS: Of the 126 patients, 48 (38%) patients were classified as NP and 78 (62%) as TR. Mean time to disease recurrence was 7.3 years for NP versus 5.6 years for TR (P = 0.0669). The patients with NP had improved 10-year rates of overall survival (NP 77% vs. TR 46%, P = 0.0002), cause-specific survival (NP 83% vs. TR 49%, P = 0.0001), and distant disease-free survival (NP 77% vs. TR 26%, P < 0.0001). Patients with NP more often developed contralateral breast carcinoma (10-year rate: NP 29% vs. TR 8%, P = 0.0043), but were less likely to develop a second local recurrence after salvage treatment of the first IBTR (NP 2% vs. TR 18%, P = 0.008). CONCLUSIONS: Patients with NP had significantly better survival rates than those with TR, but were more likely to develop contralateral breast carcinoma. Distinguishing new breast carcinomas from local disease recurrences may have importance in therapeutic decisions and chemoprevention strategies. This is because patients with new carcinomas had significantly lower rates of metastasis than those with local disease recurrence, but were more likely to develop contralateral breast carcinomas. 相似文献
110.
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy 总被引:15,自引:2,他引:13
Mirza NQ Vlastos G Meric F Buchholz TA Esnaola N Singletary SE Kuerer HM Newman LA Ames FC Ross MI Feig BW Pollock RE McNeese M Strom E Hunt KK 《Annals of surgical oncology》2002,9(3):256-265
Background Our aim was to identify predictors of locoregional recurrence (LRR) in patients with early-stage breast cancer treated with
breast-conserving therapy (BCT) and long-term follow-up.
Methods From 1970 to 1994, 1153 patients with stage I to II breast cancer underwent BCT and radiotherapy at our institution. Patients
with prior breast cancer or other primary malignancies were excluded. Clinical and pathologic characteristics evaluated were
age, race, tumor size, stage, pathologic tumor margins, axillary nodal involvement, estrogen and progesterone receptor status,
Black's nuclear grade, type of surgery, and use of adjuvant therapy.
Results Of 1083 patients, 54% presented with stage I disease and 46% with stage II disease. Median age was 50 years, and median follow-up
was 9 years. Axillary nodes were positive in 31% of the patients who underwent axillary dissection. LRR developed in 6%, LRR
followed by systemic recurrence in 5%, and systemic recurrence alone in 13%, 76% had no evidence of recurrence at last follow-up.
Age, tumor size, positive lymph nodes, and not receiving chemotherapy or hormonal therapy were independent predictors of LRR.
Disease-specific survival among patients with LRR was similar to that among patients with no recurrence.
Conclusions Multidisciplinary treatment strategies should be used to accomplish durable locoregional control after BCT.
Presented at the 54th Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, March 15–18, 2001. 相似文献